Texting while Sleepwalking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There has been no official announcement RBL is complete. Most likely a Tuesday Pr announcing completion. Hopefully that will contain more insight into the IND app timing. Ipix doesn't control when grants are reviewed but he felt we would hear by mid September which may coincide with early September IND comment.
well at least the large blocks come via etrade (aka retail)
this was yesterday's 400k bidder (which etrf today is showing up as the seller with size)
can't wait till we move on from being controlled by a few individuals making constant ATM runs... wash, rinse, repeat till we finally get out of this trading range
If a MM allocates a sell report to a client without actually executing the stock, their trading pad goes long
For example, customer Max enters a sale of 10,000 shares at .235
If the order doesn't get routed through SOES, it gets sent to either an agency or principal trader to get filled.
Tian is the trader with a flat position. The trader can just allocate a sell report to the customer's account at .235 without ever executing the stock. What happens is customer Max receives a sell repot at .235 and Tian just made his pad go long 10,000 share a .235
If we finally get the slow burn to the upside as trades appear to be hitting the bid, don't be fooled.
Just an FYI, the same holds true in reverse if Tian has a flat position in his trading pad, gives customer Max a buy report at .235, now trader Tian is short 10,000 at .235. This is just accounting 101. Max is long 10,000 at Tian goes short this same amount. This is what happens when a stock loses momentum on an intraday pop. These mm's have limit display screens that show when buy momentum slows in a stock and they can't just hold the line at a specific PPS before dropping it to finally cover their position
so what's next on the wish list. we had SI.... done. people wanted additions to the company... done. what's next? do i hear grant money? big name collaboration?
Flippers getting taken out.... will this be the final bye-bye (buy - buy)
kinda interesting the new guy talked about oral brilacidin and not IV
I am glad they stopped with the 8AM PR's
right at the market open. keeping everyone on their toes
If we use t/a we just need to stay above the downtrend resistance line. We are in back test mode. With an ind coming up in the next few weeks along with hearing back on grant(s) you would think that will have the pps go up in anticipation before news hits.
We are on the outside looking in. Since we have this MTA in place we are not sure what IPIX can and can't report at this time. Per the June 5 GMU announcement ipix paid for the ec50 value. Leo said this was so we could proceed with the ind. Maybe the data we received to date was on the path to obtaining this value. Who knows what other testing may have happened since March? It obviously guided ipix in coming up with the July 13 pr as you pointed out. Cant believe this would be a shrug of the shoulders kind of decision
Just got to be patient for human trials. We need to go from pre-clinical to P2 trials to get investor's attention. I know when I would screen covid plays the most difficult part was waiting out pre clinical data. It was easier to find more interest in covid plays already in human trials.
The above being said our daily volume dollar amount is so low that any outside 3rd party can control the pps. A few bid whacks takes us down. I know aspire has a no shorting clause but these financing companies loves financing depressed companies for better terms.
And this is the data ipix paid gmu for so we could file the ind for human trials. Nice twisring. I am starting to see why others get so outraged on ur view
Its the ic50 value to show the lowest effective dosing.
From the pr
Brilacidin has now exhibited robust in vitro anti-SARS-CoV-2 efficacy at low concentrations, well below already established clinically-achievable concentrations based on pharmacokinetics observed in the Company’s Phase 2b clinical trial of Brilacidin in Acute Bacterial Skin and Skin Structure Infections.
the PR shows up on thinkorswim but not the td site or app
also, the company did not 8k yesterday's PR like that have been doing in the past
as for some other poster earlier today complaining about why there is a paragraph in the PR about covid partners/collaborations, it wasn't too long ago that the same paragraph failed to show up in a pr or 2 and the complaints started rolling in why the paragraph was missing. whatever the case, you are right if it makes you feel better
i think if the fda approves our ind for human trials that should bump the price. getting our status from pre-clinical to P2 trials will confirm validation. all the pragmatic theories are getting kind of old
per my call with the ceo a few weeks back, we should be hearing mid-september on grant(s). he is basing it on the current 2-3 month turnaround time.
rbl data might bump the pps as well if we start showing up in various spreadsheets showing our in vitro data compared to other compounds
There was a paragraph that referenced 2 external articles:
Playing devils advocate is totally fine to balance out the conversation. The thing that is clear on both sides of the conversation is no one knows anything about trial design. We are all reading the tea leaves (and some are apparently smoking them too)
i was thinking the same thing. being over 300 is strong, but a firm number would have come across as actual info and not hearsay from the rbl. today's pr did not say testing was over and maybe the rbl will report the actual number in their peer review doc
Just checked the percent change loser board today and a lot of covid plays are on there. there are a few strong covid plays today and I would have loved to see IPIX hold it's gain right out of the gate. it's better we close the gap today then have it be a 'fear' topic over the next few days.
IPIX did rally from it's 52 wk low, but it has not experienced the true appreciation other covid plays have made to date. I don't wish a 2nd wave on anyone since that would mean loss of life, but if there is a 2nd wave, IPIX timing couldn't be better (flu season starts in fall and peaks in winter)
i agree. not sure if the CRO has anything to do with it but i believe cytodyn was able to treat patients via compassionate use.... and there CRO is amarex. Amarex seems on the ball
IPIX compassionate use link:
http://www.ipharminc.com/expanded-access-and-compassionate-use
i wonder if ipix goes with Amarex as our CRO
+300 SI for a therapeutic showing viral inhibition from a RBL lab
move over bacon here comes sizzlean
What's the FDA gonna say, "no, we are not interested" at the CTAP meeting?
Last Paragraph says a lot - he should have broken this up into 2 PRs today
looking forward to the analysis of our SI compared to our peers. There were 2 docs referenced in today's PR. When Brilacidin shows up in future similar documentation as being compared to the very select few thus far, we are going into the stratosphere.... people will be like "i could have bought a penny stock under the radar and now i have to pay dollars!?!"
September should be a good month here. Based on the progression of news up until today's PR, if everything comes to fruition, this will no longer be a penny stock by end of September.
So a 300 SI is almost double the 152.7
this is just a joke for those of you with a sense of humor this a.m.
Brilacidin might be a line item with many other therapeutics however where are all the other GMU announcements that those other drugs have advanced to obtaining the ec50 values? Hmmmmmm. I cant find any other drug being researched in this fashion at gmu. Remember this was not an ipix pr but rather a GMU announcement longs came across.
Call the company. You need to push the option to speak with the ceo.
My position has been ipix is going along for the ride. Leo did not pursue covid but rather other institutions came to ipix looking into brilacidin. I think leo was a reluctant passenger until May when he forked over the 35k. Now he is taking it more serious with input from the rbl who submitted their grant in June. Leo also said he expects to hear back on grant in September based upon 2-3 month review time
The ceo will speak with investors. I called and he spent a few minutes on the phone with me answering questions. Once we get the ec50 value from gmu, he brought this up not me, then we can submit ind for human trials. He thought he did a good job to get all this research done for 35k.
someone was hitting the ask. the bid got tapped by some flippers but the ask kept getting tapped.
i don't believe much of what get's posted here as to who owns what shares or their strategies. flippers exist. investors exist. bag holders exist.
I really don't know that many people willing to put 6 figures into a pink sheet stock, especially not someone telegraphing their every play to a rather low volume stock such as IPIX
if someone can afford $500 worth of IPIX, so be it
Let's see if having independent labs analysis of Brilacidin will paint a different story then the non-stop self promotion of one of those stocks you brought up.
Someone wanted in before the weekend. nice close!!
Fiction galore today. Imagine this board was as quiet as it should be based on no news yet anticipation of potential great results... however that is not the case.
Aha! Lol
Getting 3rd party validation of results should help. Pubcos are pubcos to to tap the markets to raise money. Even though it's obvious some of the wording is 'copy and paste' from the GMU researcher, hence the 3x elucidate has been used since Feb via PR as well as the 2019 report released by the GMU researcher, it just seems all we are seeing is fluff news so the company can dilute to raise cash. I get it. I totally get it.
and you are right, no news is scary too because we don't want to be a bagholder when everyone else has left the party
I did contact the PR person on the GMU June 5th update. She said she didn't have more info on the announcement and to contact the professor. I just would like to know how the undergrad received the information that Brilacidin was part of a project at GMU in the first place when the shareholders are in the dark as to which rbl, phri and/or university
I saw what that short and distort guy tried to do over at a fellow otc covid play. With covid plays displaying weakness, its best to wait for a blockbuster update. I like how ipix has pumped the brakes creating more anticipation for the RBL data. Till then it will be the few flippers here competing against themselves on a daily basis.
8 trading days, 12 calendar days (including today)
Keep positive cause the update will come.
Including today, there are 8 trading days left in the month (unless there is a holiday I have overlooked again)
Even as an otc stock, we should have experienced a buy the rumor sell the news type of run.
Fingers crossed the RBL data does conclude this month to keep the minimal time frames we have been by given in tact
My favorite gripe is that the company doesn't issue enough news along with the company issuing too many fluff prs.
ipix is doing the right thing now. just waiting for a real material update to get this dog and pony show up and running again
i saw a new article today the wolf of wall st is back on RB and pushing penny stocks. last time he started pushing the pinks, the stinky pinkies made many millionaires